UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$388M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$359M |
| 3 |
ExxonMobil
XOM
|
+$284M |
| 4 |
TSMC
TSM
|
+$259M |
| 5 |
iShares China Large-Cap ETF
FXI
|
+$239M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$911M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$825M |
| 3 |
UBS Group
UBS
|
+$683M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$381M |
| 5 |
Willis Towers Watson
WTW
|
+$375M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.08% |
| 2 | Financials | 7.19% |
| 3 | Healthcare | 6.35% |
| 4 | Consumer Discretionary | 5.55% |
| 5 | Industrials | 4.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2801
Karyopharm Therapeutics
KPTI
$44.4M
| $3.82M | ﹤0.01% |
34,564
+16,764
| +94% | +$2.09M |
|
2802
Cullen/Frost Bankers
CFR
$10.3B
| $3.82M | ﹤0.01% |
27,586
-30,254
| -52% | -$4.21M |
|
|
DCPH
2803
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $3.82M | ﹤0.01% |
411,978
-34,401
| -8% | -$293K |
|
2804
WhiteHorse Finance
WHF
$144M
| $3.81M | ﹤0.01% |
252,948
-25,842
| -9% | -$393K |
|
2805
WisdomTree Emerging Markets SmallCap Dividend Fund
DGS
$1.77B
| $3.81M | ﹤0.01% |
71,542
-43,196
| -38% | -$2.27M |
|
2806
Gevo
GEVO
$382M
| $3.81M | ﹤0.01% |
814,685
-130,500
| -14% | -$499K |
|
2807
iShares ESG Advanced High Yield Corporate Bond ETF
HYXF
$195M
| $3.81M | ﹤0.01% |
78,453
-38,923
| -33% | -$1.92M |
|
2808
CALL
Abbott
ABT
$188B
| $3.81M | ﹤0.01% |
32,200
-182,600
| -85% | -$22.6M |
|
|
KRTX
2809
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $3.8M | ﹤0.01% |
30,000
+28,242
| +1,606% | +$3.18M |
|
|
EOI
2810
Eaton Vance Enhanced Equity Income Fund
EOI
$828M
| $3.8M | ﹤0.01% |
206,513
+16,779
| +9% | +$316K |
|
2811
uniQure
QURE
$3.2B
| $3.8M | ﹤0.01% |
210,180
+62,551
| +42% | +$1.09M |
|
2812
Nuveen California Municipal Value Fund
NCA
$303M
| $3.79M | ﹤0.01% |
413,827
-48,401
| -10% | -$466K |
|
|
OPP
2813
RiverNorth/DoubleLine Strategic Opportunity Fund
OPP
$192M
| $3.79M | ﹤0.01% |
307,903
-8,777
| -3% | -$117K |
|
2814
State Street SPDR Dow Jones International Real Estate ETF
RWX
$267M
| $3.79M | ﹤0.01% |
111,117
+9,085
| +9% | +$307K |
|
2815
BioXcel Therapeutics
BTAI
$28.7M
| $3.78M | ﹤0.01% |
11,285
-1,211
| -10% | -$351K |
|
2816
CALL
Virgin Galactic
SPCE
$415M
| $3.77M | ﹤0.01% |
19,083
-6,165
| -24% | -$1.15M |
|
|
NPTN
2817
DELISTED
NEOPHOTONICS CORP
NPTN
| $3.77M | ﹤0.01% |
247,918
+214,440
| +641% | +$3.27M |
|
2818
Beam Therapeutics
BEAM
$2.82B
| $3.77M | ﹤0.01% |
65,758
+27,174
| +70% | +$1.78M |
|
|
AVLR
2819
DELISTED
Avalara, Inc.
AVLR
| $3.77M | ﹤0.01% |
37,847
+7,280
| +24% | +$738K |
|
2820
CALL
Kohl's
KSS
$2.16B
| $3.76M | ﹤0.01% |
62,200
-73,200
| -54% | -$4.13M |
|
2821
EQT Corp
EQT
$33.8B
| $3.76M | ﹤0.01% |
109,270
-396,424
| -78% | -$9.67M |
|
2822
VanEck Low Carbon Energy ETF
SMOG
$134M
| $3.76M | ﹤0.01% |
25,880
-12,667
| -33% | -$1.77M |
|
2823
BlackRock MuniYield New York Quality Fund
MYN
$376M
| $3.75M | ﹤0.01% |
309,722
-16,551
| -5% | -$213K |
|
2824
Graphic Packaging
GPK
$3.53B
| $3.75M | ﹤0.01% |
186,922
-7,007
| -4% | -$136K |
|
|
ITCI
2825
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.75M | ﹤0.01% |
61,220
+20,772
| +51% | +$1.08M |
|
Similar funds
UBS Group's Q1 2022 Portfolio in Review
As of Q1 2022, UBS Group held 11,668 positions worth $300B, down 14% from $349B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
UBS Group withdrew a net $29.5B in Q1 2022, closing 1,161 positions and reducing 5,174 holdings. Its most notable exit was Xilinx Inc, an estimated $186M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 12% a quarter earlier, followed by Financials and Healthcare.
Against the trend, UBS Group opened a new position in Shell worth $66.6M.
- UBS Group's largest Q1 2022 buy was Shell: 1,213,213 shares worth $66.6M.
- UBS Group added most to Tesla in Q1 2022, an estimated $388M increase.
- UBS Group's biggest Q1 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $911M.
- UBS Group fully exited Xilinx Inc in Q1 2022, selling an estimated $186M.
- UBS Group's ten largest holdings make up 13% of its $300B portfolio in Q1 2022.
- UBS Group opened 1,181 new positions and closed 1,161 in Q1 2022.
- UBS Group's portfolio value fell 14% quarter-over-quarter to $300B.
Based on UBS Group's 13F filing for Q1 2022, filed 16 May 2022.